Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

82 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prediction of cardiovascular risk factors from retinal fundus photographs: Validation of a deep learning algorithm in a prospective non-interventional study in Kenya.
White T, Selvarajah V, Wolfhagen-Sand F, Svangård N, Mohankumar G, Fenici P, Rough K, Onyango N, Lyons K, Mack C, Nduba V, Noorali Saleh M, Abayo I, Siddiqui A, Majdanska-Strzalka M, Kaszubska K, Hegelund-Myrback T, Esterline R, Manzur A, Parker VER. White T, et al. Among authors: fenici p. Diabetes Obes Metab. 2024 Jul;26(7):2722-2731. doi: 10.1111/dom.15587. Epub 2024 Apr 15. Diabetes Obes Metab. 2024. PMID: 38618987
HbA1c trajectories over 3 years in people with type 2 diabetes starting second-line glucose-lowering therapy: The prospective global DISCOVER study.
Bongaerts B, Kuss O, Bonnet F, Chen H, Cooper A, Fenici P, Gomes MB, Hammar N, Ji L, Khunti K, Medina J, Nicolucci A, Shestakova MV, Watada H, Rathmann W. Bongaerts B, et al. Among authors: fenici p. Diabetes Obes Metab. 2023 Jul;25(7):1890-1899. doi: 10.1111/dom.15050. Epub 2023 Apr 5. Diabetes Obes Metab. 2023. PMID: 36906837
Glycaemic control in patients with type 2 diabetes initiating second-line therapy: Results from the global DISCOVER study programme.
Khunti K, Chen H, Cid-Ruzafa J, Fenici P, Gomes MB, Hammar N, Ji L, Kosiborod M, Pocock S, Shestakova MV, Shimomura I, Tang F, Watada H, Nicolucci A; DISCOVER investigators. Khunti K, et al. Among authors: fenici p. Diabetes Obes Metab. 2020 Jan;22(1):66-78. doi: 10.1111/dom.13866. Epub 2019 Oct 1. Diabetes Obes Metab. 2020. PMID: 31468637 Free PMC article.
Association of sodium-glucose cotransporter-2 inhibitors with outcomes in type 2 diabetes with reduced and preserved left ventricular ejection fraction: Analysis from the CVD-REAL 2 study.
Lam CSP, Karasik A, Melzer-Cohen C, Cavender MA, Kohsaka S, Norhammar A, Thuresson M, Chen H, Wittbrodt E, Fenici P, Kosiborod M; CVD-REAL Investigators and Study Group. Lam CSP, et al. Among authors: fenici p. Diabetes Obes Metab. 2021 Jun;23(6):1431-1435. doi: 10.1111/dom.14356. Epub 2021 Mar 23. Diabetes Obes Metab. 2021. PMID: 33606906 Free PMC article.
Treatment patterns and glycated haemoglobin levels over 36 months in individuals with type 2 diabetes initiating second-line glucose-lowering therapy: The global DISCOVER study.
Charbonnel BH, Chen H, Cid-Ruzafa J, Cooper A, Fenici P, Gomes MB, Saraiva GL, Medina J, Nicolucci A, Shestakova MV, Shimomura I, Surmont F, Tang F, Vora J, Watada H, Khunti K; DISCOVER Investigators. Charbonnel BH, et al. Among authors: fenici p. Diabetes Obes Metab. 2023 Jan;25(1):46-55. doi: 10.1111/dom.14842. Epub 2022 Sep 16. Diabetes Obes Metab. 2023. PMID: 36111434 Free PMC article.
Lower risk of cardiovascular events and death associated with initiation of sodium-glucose cotransporter-2 inhibitors versus sulphonylureas: Analysis from the CVD-REAL 2 study.
Goh SY, Kosiborod MN, Lam CSP, Cavender MA, Kohsaka S, Norhammar A, Birkeland KI, Holl RW, Mauricio D, Tangri N, Shaw JE, Thuresson M, Fenici P, Kim DJ; CVD-REAL Investigators and Study Group. Goh SY, et al. Among authors: fenici p. Diabetes Obes Metab. 2023 Aug;25(8):2402-2409. doi: 10.1111/dom.15092. Epub 2023 May 8. Diabetes Obes Metab. 2023. PMID: 37055714 No abstract available.
Global patterns of comprehensive cardiovascular risk factor control in patients with type 2 diabetes mellitus: Insights from the DISCOVER study.
Patel KK, Gomes MB, Charbonnel B, Chen H, Cid-Ruzafa J, Fenici P, Hammar N, Ji L, Kennedy KF, Khunti K, Kosiborod M, Pocock S, Shestakova MV, Shimomura I, Surmont F, Watada H, Arnold SV. Patel KK, et al. Among authors: fenici p. Diabetes Obes Metab. 2021 Jan;23(1):39-48. doi: 10.1111/dom.14180. Epub 2020 Sep 22. Diabetes Obes Metab. 2021. PMID: 32845558 Free PMC article.
Prevalence and progression of chronic kidney disease among patients with type 2 diabetes: Insights from the DISCOVER study.
Khunti K, Charbonnel B, Chen H, Cherney DZ, Cooper A, Fenici P, Gomes MB, Hammar N, Heerspink HJL, Ji L, Medina J, Nicolucci A, Ramirez L, Rathmann W, Shestakova MV, Shimomura I, Tang F, Watada H, Kosiborod M; DISCOVER Investigators. Khunti K, et al. Among authors: fenici p. Diabetes Obes Metab. 2021 Aug;23(8):1956-1960. doi: 10.1111/dom.14401. Epub 2021 May 3. Diabetes Obes Metab. 2021. PMID: 33852196
82 results